NCT06738563

Brief Summary

Exclusive breastfeeding during the first six months of life and continued breastfeeding for at least 24 months constitute the optimal feeding method for infants and young children. However, breast milk and breastfeeding can be significant pathways for the transmission of certain viruses. The objective of this study is to examine the influence of human breast milk and its composition on viral infectivity and viral transmission of the HTLV-1 virus and arboviruses such as Zika virus, yellow fever, dengue, and tick-borne encephalitis.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
53mo left

Started Sep 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Sep 2025Sep 2030

First Submitted

Initial submission to the registry

December 4, 2024

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 17, 2024

Completed
9 months until next milestone

Study Start

First participant enrolled

September 10, 2025

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2028

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2030

Last Updated

December 15, 2025

Status Verified

December 1, 2024

Enrollment Period

3 years

First QC Date

December 4, 2024

Last Update Submit

December 8, 2025

Conditions

Keywords

MilkMaternalVirusTransmissionInfectivity

Outcome Measures

Primary Outcomes (1)

  • Study the influence of breast milk and its composition on viral infectivity and oral transmission of HTLV-1 and arboviruses such as Zika virus, yellow fever virus, dengue virus, and tick-borne encephalitis virus.

    Various viruses will be incubated with milk samples. The influence of milk on the different viruses will be studied. The capacity of these viruses incubated with milk to infect the target cells (immune or epithelial cells, depending on the virus) will be measured (measurement of the number of infected cells).

    36 months

Secondary Outcomes (3)

  • Determine the antiviral or proviral mechanisms of certain biological factors in breast milk.

    36 months

  • Determine the role of breast milk in the mechanisms by which the relevant viruses cross an epithelium.

    36 months

  • Determine the influence of a few hours of incubation at 4°C (refrigeration) on the previously mentioned mechanisms.

    36 months

Study Arms (1)

Lactating women

Lactating adult women who donate their milk

Other: Collection breast milk

Interventions

Collection of a milk sample taken as part of women's donation

Lactating women

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Breastfeeding adult women who register with the Île-de-France Milk Bank to donate their milk.

You may qualify if:

  • Age \> 18 years
  • Female gender
  • Lactarium Ile-de-France donors
  • Subjects covered by a Social Security scheme, excluding State Medical Aid
  • \- Women opposing participation in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lactarium Ile-de-France, Necker-Enfents Malades Hospital

Paris, 75015, France

RECRUITING

MeSH Terms

Conditions

Breast Milk ExpressionVirus Diseases

Condition Hierarchy (Ancestors)

Breast FeedingFeeding BehaviorBehaviorInfections

Study Officials

  • Virginie RIGOURD, Dr

    Lactarium Ile-de-France, Necker-Enfents Malades Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Aurore VIDY-ROCHE, PhD

CONTACT

Pierre-Emmanuel CECCALDI, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2024

First Posted

December 17, 2024

Study Start

September 10, 2025

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2030

Last Updated

December 15, 2025

Record last verified: 2024-12

Locations